Inotropic Effects of Endothelin-1: Interaction With Molsidomine and With BQ 610

Hypertension

Volumn 33, Issue 1, 1999, Pages 145-152

  Beyer, Martin E ^a   Slesak, Gunther ^a   Hovelborn, Tobias ^a   Kazmaier, Silke ^a   Nerz, Stefan ^a   Hoffmeister, Hans Martin ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BQ 610; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR; MOLSIDOMINE;

ANIMAL EXPERIMENT; ARTICLE; CORONARY ARTERY BLOOD FLOW; DRUG ANTAGONISM; DRUG EFFECT; HEART LEFT VENTRICLE PRESSURE; HEART MUSCLE CONTRACTILITY; HEART MUSCLE ISCHEMIA; HEART MUSCLE METABOLISM; HEART OUTPUT; INOTROPISM; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; VASOCONSTRICTION; VASOMOTOR REFLEX;

ANIMALS; CORONARY CIRCULATION; DATA INTERPRETATION, STATISTICAL; DRUG INTERACTIONS; ENDOTHELIN-1; ENERGY METABOLISM; HEART; HEMODYNAMIC PROCESSES; MALE; MOLSIDOMINE; MYOCARDIAL CONTRACTION; MYOCARDIUM; OLIGOPEPTIDES; PHOSPHATES; RATS; VASODILATOR AGENTS;

EID: 0032917085     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/01.HYP.33.1.145     Document Type: Article

References (47)

1. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K, Masaki T. A novel potent constrictor peptide produced by vascular endothelial cells. Nature. 1988;332:411-415.
2. Toyo-oka T, Aizawa T, Suzuki N, Hirata Y, Miyauchi T, Shin WS, Yanagisawa M, Masaki T, Sugimoto T. Increased plasma level of endothelin-1 and coronary spasm induced in patients with vasospastic angina pectoris. Circulation. 1991;83:476-483.
3. Qiu S, Theroux P, Marcil M, Solymoss BC. Plasma endothelin-1 levels in stable and unstable angina. Cardiology. 1993;82:12-19.
4. Miyauchi T, Yanagisawa M, Tomizawa T, Sugishita Y, Suzuki N, Fujino M, Ajisaka R, Goto K, Masaki T. Increased plasma concentrations of endothelin-1 and big endothelin-1 in acute myocardial infarction. Lancet. 1989;2:747. Letter.
5. Stewart DJ, Kubac G, Costello KB, Cernacek P. Increased plasma endothelin-1 in the early hours of acute myocardial infarction. J Am Coll Cardiol. 1991;18:38-43.
6. Rodeheffer RJ, Lerman A, Heublein DM, Burnett JC. Increased plasma concentrations of endothelin in congestive heart failure in humans. Mayo Clin Proc. 1992;67:719-724.
7. Arai H, Hori S, Aramori I, Ohkubo H, Nakanishi S. Cloning and expression of a cDNA encoding an endothelin receptor. Nature. 1990;348:730-732.
8. Sakurai T, Yanagisawa M, Takuwa Y, Miyazaki H, Kimura S, Goto K, Masaki T. Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor. Nature. 1990;348:732-735.
9. Hu JR, von Harsdorf R, Lang RE. Endothelin has potent inotropic effects in rat atria. Eur J Pharmacol. 1988;158:275-278.
10. Ishikawa T, Yanagisawa M, Kimura S, Goto K, Masaki T. Positive inotropic action of novel vasoconstrictor peptide endothelin on guinea pig atria. Am J Physiol. 1988;255:H970-H973.
11. Moravec CS, Reynolds EE, Stewart RW, Bond M. Endothelin is a positive inotropic agent in human and rat heart in vitro. Biochem Biophys Res Commun. 1989;159:14-18.
12. + exchanger. Circ Res. 1991;86:269-279.
13. Karwatowska-Prokopczuk E, Wennmalm A. Effects of endothelin on coronary flow, mechanical performance, oxygen uptake, and formation of purines and on outflow of prostacyclin in the isolated rabbit heart. Circ Res. 1990;66:46-54.
14. Neubauer S, Ertl G, Haas U, Pulzer F, Kochsiek K. Effects of endothelin-1 in isolated perfused rat heart. J Cardiovasc Pharmacol. 1990;16:1-8.
15. Domenech R, Macho P, Gonzalez R. Huidobro-Toro JP. Effect of endothelin on total and regional coronary resistance and on myocardial contractility. Eur J Pharmacol. 1991;192:409-416.
16. Yang X-P, Madeddu P, Micheletti R, English E, Rossi R, Giacalone G, Benatti P, Bianchi G. Effects of intravenous endothelin on hemodynamics and cardiac contractility in conscious Milan normotensive rats. J Cardiovasc Pharamacol. 1991;17:662-669.
17. Beyer ME, Nerz S, Kramer BK, Hoffmeister HM. Hemodynamic and inotropic effects of endothelin-1 in vivo. Basic Res Cardiol. 1994;89:39-49.
18. Beyer ME, Nerz S, Kazmaier S, Hoffmeister HM. Effect of endothelin-1 and its combination with adenosine on myocardial contractility and myocardial energy metabolism in vivo. J Mol Cell Cardiol. 1995;27:1989-1997.
19. B receptors for myocardial contractility and myocardial energy metabolism. J Pharmacol Exp Ther. 1996;278:1228-1234.
20. Majid PA, DeFeyter PJF, Van der Wall EE, Wardeh R, Roos JP. Molsidomine in the treatment of patients with angina pectoris: acute hemodynamic effects and clinical efficacy. N Engl J Med. 1980;302:1-6.
21. A receptors. In: Schneider CH, Eberele AN, eds. Peptides. Leiden, Netherlands: ESCOM; 1992;685-686.
22. Cornet S, Teillot M, Pirotzky E, Braquet P. Cicletanine modulates endothelin-induced renal vasoconstriction in the rat. J Cardiovasc Pharmacol. 1991;17:S319-S321.
23. D-receptor antagonist, BQ 788. Proc Natl Acad Sci U S A. 1994;91:4892-4896.
24. Kowallik P, Schulz R, Guth BD, Schade A, Paffhausen W, Gross R, Heusch G. Measurements of regional myocardial blood flow with multiple colored microspheres. Circulation. 1991;83:974-982.
25. Atkinson DE. The energy charge of the adenylate pool as a regulatory parameter: interaction with feedback modifiers. Biochemistry. 1968;11:4030-4034.
26. Sakurai T, Yanagisawa M, Masaki T. Molecular characterization of endothelin receptors. Trends Pharmacol Sci. 1992;13:103-108.
27. Fukuroda T, Nishikibe M, Ohta Y, Ihara M, Yano M, Ishikawa K, Fukani T, Ikemoto F. Analysis of responses to endothelins in isolated porcine blood vessels by using a novel endothelin antagonist, BQ-153. Life Sci. 1992;50:PL107-PL112.
28. B) mediate vasoconstriction in the perfused rat heart. J Cardiovasc Pharmacol. 1993;22(suppl 8):S248-S251.
29. Fujitani Y, Ueda H, Okada T, Urade Y, Karaki H. A selective agonist of endothelin type B receptor, IRL 1620, stimulates cyclic GMP increase via nitric oxide formation in rat aorta. J Pharmacol Exp Ther. 1993;267:683-689.
30. B receptor in endothelial cells: receptor coupling to nitric oxide synthase. J Biol Chem. 1994;269:21778-21785.
31. Feelisch M, Noak E. Correlation between nitric oxide formation during degradation of organic nitrates and activation of guanylate cyclase. Eur J Pharamacol. 1987;139:19-30.
32. Kuhn M, Forstermann U. Endothelium-dependent vasodilation in human epicardial coronary arteries: effect of prolonged exposure to glyceryl trinitrate or SIN-1. J Cardiovasc Pharmacol. 1989;14(suppl 11):S47-S54.
33. B-receptor mediated effects of endothelin-1 and [Ala [1,3,11,15]] endothelin-1 by BQ 123 in the anaesthetized rat. Br J Pharmacol. 1992;107:912-918.
34. A receptor subtype in the anaesthetized rat: effect of BQ 123 on systemic haemodynamic responses. Eur J Pharmacol. 1992;221:315-324.
35. Cornet S, Pirotzky E, Braquet P. Implication of different endothelin receptors in the vascular action of a hypertensive dose of ET-1 in rats. J Cardiovasc Pharmacol. 1993;22(suppl 8):S239-S242.
36. Han H, Neubauer S, Braeker B, Ertl G. Endothelin-1 contributes to ischemia/reperfusion injury in isolated rat heart-attenuation of ischemic injury by the endothelin-1 antagonists BQ 123 and BQ 610. J Mol Cell Cardiol. 1995;27:761-766.
37. Shetty SS, Okada T, Webb RL, del Grande D, Lappe RW. Functionally distinct endothelin B receptors in vascular endothelium and smooth muscle. Biochem Biophys Res Commun. 1993;191:459-464.
38. B receptors in canine coronary arteries. Circ Res. 1994;74:105-114.
39. Deng L-Y, Li J-S, Schiffrin EL. Endothelin receptor subtypes in resistance arteries from humans and rats. Cardiovasc Res. 1995;29:532-535.
40. Ishikawa T, Yanagisawa M, Kimura S, Goto K, Masaki T. Positive chronotropic effects of endothelin, a novel endothelium-derived vasoconstrictor peptide. Pflugers Arch. 1988;413:108-110.
41. Kitayoshi T, Watanabe T, Shimamoto N. Cardiovascular effects of endothelin in dogs: positive inotropic action in vivo. Eur J Pharmacol. 1989;166:519-522.
42. Mir AK, Berthold H, Scholtysik GE, Fozard JR. Cardiovascular effects of endothelin-1 in pithed spontaneously hypertensive rats: evaluation of its mechanism(s) of action. Naunyn-Schmiedebergs Arch Pharmacol. 1989;340:424-430.
43. B receptor agonist, IRL 1620, causes vasodilatation and inhibits ex vivo platelet aggregation in the anaesthetised rabbit. Eur J Pharmacol. 1994;259:51-55.
44. max in isolated canine hearts. Basic Res Cardiol. 1981;76:89-105.
45. Pfeffer MA, Pfeffer JM. Left ventricular hypertrophy and pressure generating capacity in aging genetically hypertensive rats. J Cardiovasc Pharmacol. 1985;7:41-45.
46. Bassenge E, Mulsch A. Anti-ischemic actions of molsidomine by venous and large coronary dilation in combination with antiplatelet effects. J Cardiovasc Pharmacol. 1989;14(suppl 11):S23-S28.
47. Takanashi M, Endoh M. Characterization of positive inotropic effect of endothelin on mammalian ventricular myocardium. Am J Physiol. 1991;261:H611-H619.